Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma

Oncology Reports

Volumn 12, Issue 4, 2004, Pages 805-810

  Tokinaga, Kenji ^a   Okuda, Heiwa ^a   Nomura, Asuka ^a   Ashida, Shingo ^a   Furihata, Mutsuo ^a   Shuin, Taro ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Methylation; RASSF1A; Renal cell carcinoma

Indexed keywords

DNA; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

ADENOCARCINOMA; ARTICLE; CANCER STAGING; CELL CULTURE; GENETICS; HUMAN; JAPAN; KIDNEY TUMOR; MUTATION; PATHOLOGY; PROMOTER REGION;

ADENOCARCINOMA, CLEAR CELL; DNA; HUMANS; JAPAN; KIDNEY NEOPLASMS; MUTATION; NEOPLASM STAGING; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 16644382907     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.4.805     Document Type: Article

References (27)

1. Thoenes W, Storkel S and Rumpelt HJ: Histopathology and classification of renal cell tumors (adenomas oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 181: 125-143, 1986. (Pubitemid 16021498)
2. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MMF, Crossey PA, Richards FM, Cairns P, Affara NA, Ferguson-Smith MA, Buys CHCM and Maher ER: Somatic mutations of the von Hippel-Lindau disease tumor suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Genet 3: 2169-2173, 1994.
3. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lerman MI, Zbar B and Linehan WM: Mutations of the VHL tumor suppressor gene in renal carcinoma. Nature Genet 7: 85-90, 1994. (Pubitemid 24232386)
4. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DSR, Gnarra JR, Linehan WM and Baylin SB: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700-9704, 1994. (Pubitemid 24311875)
5. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, Lerman MI and Yao M: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54: 2852-2855, 1994.
6. Shuin T, Kondo K, Ashida S, Okuda H, Yoshida M, Kanno H and Yao M: Germline and somatic mutations in von Hippel-Lindau disease gene and its significance in the development of kidney cancer. Contrib Nephrol 128: 1-10, 1999.
7. Hadaczek P, Siprashvili Z, Markiewski M, Domagala W, Dnick T, McCue PA, Pekarsky Y, Ohta M, Huebner K and Lubinski J: Absence or reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res 58: 2946-2951, 1998. (Pubitemid 28335067)
8. Velickovic M, Delahunt B and Grebe SK: Loss of heterozygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus. Cancer Res 59: 1323-1326, 1999. (Pubitemid 29136265)
9. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699, 2001. (Pubitemid 32492810)
10. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER and Latif F: Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumors. Oncogene 20: 1509-1518, 2001. (Pubitemid 32291201)
11. Dammann R, Yang G and Pfeifer GP: Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 61: 3105-3109, 2001. (Pubitemid 32691961)
12. Byun DS, Lee MG, Chae KS, Ryu BG and Chi SG: Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 61: 7034-7038, 2001.
13. Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG and Chi SG: Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 61: 6688-6692, 2001. (Pubitemid 32896487)
14. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G and Zabarovsky ER: The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 98: 7504-7509, 2001. (Pubitemid 32567978)
15. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F and Maher ER: Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 61: 7277-7281, 2001. (Pubitemid 32946526)
16. Yoon JH, Dammann R and Pfeifer GP: Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 94: 212-217, 2001. (Pubitemid 32911415)
17. Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat Genet 25: 315-319, 2000. (Pubitemid 30437320)
18. Toyota M and Issa JP: CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 9: 349-357, 1999. (Pubitemid 29532861)
19. Jones PA and Laird PW: Cancer epigenetics comes of age. Nat Genet 21: 163-167, 1999. (Pubitemid 29070360)
20. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10: 687-692, 2001. (Pubitemid 32331576)
21. Japanese Urological Association. The Japanese Society of Pathology. Japan Radiation Society: General rule for clinical and pathological studies on renal cell carcinoma. 3rd edition. Kanehara Company, Tokyo, 1999.
22. Clark SJ, Harrison J, Paul CL and Frommer M: High sensitivity mapping of methylated cytosines. Nucleic Acids Res 22: 2990-2997, 1994. (Pubitemid 24260626)
23. Klump B, Hsieh CJ, Dette S, Holzmann K, Kiebetalich R, Jung M, Sinn U, Ortner M, Porschen R and Gregor M: Promorter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease. Clin Cancer Res 9: 1773-1778, 2003. (Pubitemid 36554603)
24. Ashida S, Okuda H, Chikazawa M, Tanimura M, Sugita O, Yamamoto Y, Nakamura S, Moriyama M and Shuin T: Detection of circulating cancer cells with von Hippel-Lindau gene mutation in peripheral blood of patients with renal cell carcinoma. Clin Cancer Res 6: 3817-3822, 2000.
25. Ashida S, Nishimori I, Tanimura M, Onishi S and Shuin T: Effect of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. J Cancer Res Clin Oncol 128: 561-568, 2002. (Pubitemid 35244932)
26. Issa JP, Ahuja N, Toyota M, Bronner MP and Brentnall TA: Accelerated age-rerated CpG island methylation in the ulcerative colitis. Cancer Res 61: 3573-3577, 2001. (Pubitemid 32694963)
27. Vos MD, Ellis CA, Bell A, Birrer MJ and Clark GJ: Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 275: 35669-35672, 2000.